Your browser doesn't support javascript.
loading
High baseline Tie1 level predicts poor survival in metastatic breast cancer.
Tiainen, Leena; Korhonen, Emilia A; Leppänen, Veli-Matti; Luukkaala, Tiina; Hämäläinen, Mari; Tanner, Minna; Lahdenperä, Outi; Vihinen, Pia; Jukkola, Arja; Karihtala, Peeter; Aho, Sonja; Moilanen, Eeva; Alitalo, Kari; Kellokumpu-Lehtinen, Pirkko-Liisa.
Afiliación
  • Tiainen L; Department of Oncology, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, P.O. Box 100, FI-33014, Tampere, Finland. leena.tiainen@pshp.fi.
  • Korhonen EA; Department of Oncology, Tampere University Hospital, P.O. Box 2000, FI-33521, Tampere, Finland. leena.tiainen@pshp.fi.
  • Leppänen VM; Wihuri Research Institute and Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, P.O. Box 63, FI-00014, Helsinki, Finland.
  • Luukkaala T; Wihuri Research Institute and Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, P.O. Box 63, FI-00014, Helsinki, Finland.
  • Hämäläinen M; Research, Development and Innovation Centre, Tampere University Hospital and Faculty of Medicine and Health Technology, Tampere University, P.O. Box 2000, FI-33521, Tampere, Finland.
  • Tanner M; The Immunopharmacology Research Group, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, P.O. Box 100, FI-33014, Tampere, Finland.
  • Lahdenperä O; Department of Oncology, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, P.O. Box 100, FI-33014, Tampere, Finland.
  • Vihinen P; Department of Oncology, Tampere University Hospital, P.O. Box 2000, FI-33521, Tampere, Finland.
  • Jukkola A; Department of Oncology and Radiotherapy, Turku University Central Hospital, P.O. Box 52, 20521, Turku, Finland.
  • Karihtala P; Department of Oncology and Radiotherapy, Turku University Central Hospital, P.O. Box 52, 20521, Turku, Finland.
  • Aho S; Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 10, 90029 OYS, Oulu, Finland.
  • Moilanen E; Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 10, 90029 OYS, Oulu, Finland.
  • Alitalo K; Department of Oncology, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, P.O. Box 100, FI-33014, Tampere, Finland.
  • Kellokumpu-Lehtinen PL; Department of Oncology, Tampere University Hospital, P.O. Box 2000, FI-33521, Tampere, Finland.
BMC Cancer ; 19(1): 732, 2019 Jul 24.
Article en En | MEDLINE | ID: mdl-31340773
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor TIE-1 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Ethics Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Receptor TIE-1 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Ethics Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Reino Unido